Actinium Pharmaceuticals (ATNM) Accumulated Depreciation & Amortization (2021 - 2023)
Actinium Pharmaceuticals (ATNM) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with -$112000.0 as the latest value for Q4 2023.
- On a quarterly basis, Accumulated Depreciation & Amortization fell 165.12% to -$112000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$112000.0, a 165.12% decrease, with the full-year FY2023 number at -$112000.0, down 165.12% from a year prior.
- Accumulated Depreciation & Amortization was -$112000.0 for Q4 2023 at Actinium Pharmaceuticals, down from $172000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $172000.0 in Q4 2022 to a low of -$112000.0 in Q4 2023.
- A 3-year average of $65333.3 and a median of $136000.0 in 2021 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: increased 26.47% in 2022, then plummeted 165.12% in 2023.
- Actinium Pharmaceuticals' Accumulated Depreciation & Amortization stood at $136000.0 in 2021, then rose by 26.47% to $172000.0 in 2022, then crashed by 165.12% to -$112000.0 in 2023.
- Per Business Quant, the three most recent readings for ATNM's Accumulated Depreciation & Amortization are -$112000.0 (Q4 2023), $172000.0 (Q4 2022), and $136000.0 (Q4 2021).